Anixa Biosciences Inc (OQ:ANIX)
Business Focus: Biotechnology & Medical Research
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 3150 Almaden Expy Ste 250 SAN JOSE CA 95118 |
| Tel: | 1-408-7089808 |
| Website: | https://www.anixa.com |
| IR: | See website |
| Key People | ||
| Amit Kumar Chairman of the Board, Chief Executive Officer | Michael J. Catelani President, Chief Financial Officer, Chief Operating Officer, Company Secretary | |
| Business Overview |
| Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company's vaccine portfolio consists of technology focused on the immunization against specific retired proteins. |
| Financial Overview |
| For the three months ended 31 January 2024, Anixa Biosciences Inc revenues was not reported. Net loss increased 40% to $3.3M. Higher net loss reflects Marketing , general and administrative e increase of 60% to $1.5M (expense), Research and development expenses - increase of 53% to $860K (expense), Stock-based Compensation in SGA increase of 38% to $771K (expense). |
| Employees: | 4 as of Oct 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $75.09M as of Jan 31, 2024 |
| Annual revenue (TTM): | $0.21M as of Jan 31, 2024 |
| EBITDA (TTM): | -$11.90M as of Jan 31, 2024 |
| Net annual income (TTM): | -$10.74M as of Jan 31, 2024 |
| Free cash flow (TTM): | -$6.53M as of Jan 31, 2024 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 31,899,800 as of Mar 12, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.